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Abstract Background BRCA1- and BRCA2-associated
tumors appear to have distinct molecular signatures.
BRCA1-associated tumors are predominantly basal-like
cancers, whereas BRCA2-associated tumors have a pre-
dominant luminal-like phenotype. These two molecular
signatures reﬂect in part the two cell types found in the
terminal duct lobular unit of the breast. To elucidate novel
genes involved in these two spectra of breast tumorigenesis
we performed global gene expression analysis on breast
tumors from germline BRCA1 and BRCA2 mutation carri-
ers. Methodology Breast tumor RNAs from 7 BRCA1 and 6
BRCA2 mutation carriers were proﬁled using UHN human
19K cDNA microarrays. Supervised univariate analyses
were conducted to identify genes differentially expressed
between BRCA1 and BRCA2-associated tumors. Selected
discriminatory genes were validated using real time reverse
transcription polymerase chain reaction in the tumor
RNAs, and/or by immunohistochemistry (IHC) or by
in situ hybridization (ISH) on tissue microarrays (TMAs)
containing an independent set of 58 BRCA1 and 64
BRCA2-associated tumors. Results Genes more highly
expressed in BRCA1-associated tumors included stathmin,
osteopontin, TGFb2 and Jagged 1 in addition to genes
previously identiﬁed as characteristic of basal-like breast
cancers. BRCA2-associated cancers were characterized by
the higher relative expression of FGF1 and FGFR2.
FGFR2 protein was also more highly expressed in BRCA2-
associated cancers (P = 0.004). Signiﬁcance BRCA1-
associated tumours demonstrated increased expression of
component genes of the Notch and TGFb pathways
whereas the higher expression of FGFR2 and FGF1 in
BRCA2-associated cancers suggests the existence of an
autocrine stimulatory loop.
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Introduction
BRCA1- and BRCA2-associated tumors have many mor-
phologic features in common. These include ductal
histology, high histologic grade, pushing tumor margins
and a notable host lymphocytic response [1, 2]. Despite
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BRCA1-associated tumors have been shown to be pre-
dominantly estrogen receptor negative and to have a basal
phenotype [3–5], whereas we have shown previously that
BRCA2-associated tumors have a luminal phenotype
characterized by the expression of estrogen receptor and
luminal-type cytokeratins [1]. These two molecular signa-
tures reﬂect in part the two cell types, basal/myoepithelial
and luminal found in the terminal duct lobular unit of the
normal breast.
Basal-like human breast cancers have been shown to
exhibit aberrations in the epidermal growth factor receptor
(EGFR) signaling pathway [6]. With the exception of
Cyclin D1, genes responsible for promoting the growth and
survival of BRCA2-associated cancers have yet to be
identiﬁed [7]. Our objective in performing global gene
expression analysis on BRCA1- and BRCA2-associated
tumors was to distinguish these distinct pathways of car-
cinogenesis and to elucidate novel genes necessary for the
transformation and survival of BRCA2-associated tumors.
Materials and methods
Breast cancer cases
Flash frozen tumor tissue was available from 7 germline
BRCA1 carriers and 6 germline BRCA2 carriers partici-
pating in the Ontario Familial Breast Cancer Registry
(OFBCR) [8, 9] and the Ontario Cancer Genetics Network
(OCGN). Following pathologic conﬁrmation of invasive
disease, the tumor tissue was frozen and stored in liquid
nitrogen. Testing for germline mutations in BRCA1 and
BRCA2 was performed using an RNA/DNA-based protein
truncation test with complementary 50 sequencing as pre-
viously described [10]. All mutations were conﬁrmed by
DNA sequencing. Mutations were classiﬁed as deleterious
if they were protein-truncating, missense mutations (rare),
or splice-site mutations as deﬁned by the Breast Infor-
matics Consortium (http://research.nhgri.nih.gov/bic/).
The clinicopathologic characteristics and mutation sta-
tus (for the BRCA1-associated and BRCA2-associated
tumors) are summarized in Table 1. Tumors were classiﬁed
according to the WHO histologic classiﬁcation of breast
tumors [11] and graded by central pathology review using
the Nottingham histologic grading system [12]. The
pathologist was blinded to the mutational status or family
history of the participants. Receptor status was obtained by
either biochemical or immunohistochemical methods.
A validation set of formalin-ﬁxed parafﬁn-embedded
(FFPE) tumors from 58 BRCA1 carriers, 64 BRCA2 carriers
and 242 additional individuals from the OFBCR without
BRCA1 or BRCA2 mutations was used to construct tissue
microarrays (TMAs).
RNA extraction and reverse transcription
Total RNA was isolated from 20 to 50 mg of tumor tissue
using TRIzol reagent (Gibco BRL Life Technologies).
Reference RNA was a pool of 13 cell lines, modiﬁed from
the common reference cell line list [13]. Tumor and ref-
erence RNAs (5 lg) were reverse transcribed with
Table 1 Clinicopathologic
characteristics of BRCA1- and
BRCA2-associated breast
cancers
a ID: Identiﬁcation number
b ER: Estrogen receptor
c PR: Progesterone receptor
d NST: No special type
e Neg: Negative
f Equ: Equivalent
g Pos: Positive
h NA: Not available
LAB
ID
a
Mutation Type of
invasive
cancer
Age at
diagnosis
Grade Lymphatic
invasion
Blood
vessel
invasion
ER
b PR
c
BRCA1 mutation
3435 2457C-T Ductal, NST
d 50 3 Absent Absent Neg
e Neg
4080 185delAG Ductal, NST 40 3 Absent Absent Equ
f Pos
g
4326 185delAG Ductal, NST 35 3 Absent Absent NA
h Neg
1834 5293delAAAG Ductal, NST 30 3 Present Absent Neg NA
1693 5382insC Ductal, NST 44 3 Absent Absent Equ Pos
2528 4603G-T Ductal, NST 33 3 NA NA Neg Pos
3078 185delAG Ductal, NST 32 3 Present Present Neg Equ
BRCA2 mutation
4324 8765delAG Ductal, NST 44 3 Present Absent Neg Pos
4472 IVS16 + 3 A-C Ductal, NST 44 3 Absent NA Neg Neg
2172 6174delT Ductal, NST 46 3 Present NA Pos Pos
3627 9132delC Ductal, NST 34 3 Present Absent Pos Pos
4374 8765delAG Ductal, NST 58 3 Present Absent Neg Neg
3242 6764insA Ductal, NST 75 3 Present Absent Pos Equ
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123Superscript III reverse transcriptase (Invitrogen) to yield
cDNA. Tumor and reference cDNA (5 lg) were indirectly
labeled using aminoallyl nucleotide analogs with Cy3 and
Cy5 ﬂuorescent tags, respectively.
Dye labeling and cDNA array hybridisation
The labeled probes were simultaneously hybridized to
UHN human 19K cDNA microarray slides (www.
microarrays.ca), and incubated overnight at 42C. These
19K cDNA microarrays are single-spotted and contain
19,008 characterized or unknown human expressed
sequence tags (ESTs). The clone set has been sequence-
veriﬁed at the UHN Microarray Centre, Toronto. Following
hybridization the slides were washed and scanned using an
Axon scanner. Fluorescent dye swap experiments were also
performed for two tumors.
Pre-processing of expression data
The gene expression data were obtained from the original
image ﬁles as spot intensities by correcting the mean fore-
ground for each spot with the median local background. The
arrayqualitywascontrolledbyrequiringarraystohavemore
than80%ofspotswithspotintensitieshigherthantheirlocal
background and more than 75% of spots with spot intensity
higherthan1.2timestheirlocalbackgroundinbothchannels
[14].Spotswithforegroundintensitylowerthanbackground
were treated as missing. A relative expression value was
obtained for each gene as the log base 2 ratio of the adjusted
intensity for the sample channel versus the reference chan-
nel. The log2 ratios were normalized by a within-subarray
print-tip ‘‘loess’’ adjustment, followed by a between-array
scale adjustment [15]. Poor quality spots as ﬂagged by the
GenePix image analysis software were excluded from the
normalization. Pre-processing and normalization were car-
ried out using the R-Bioconductor package LIMMA [16];
http://www.Bioconductor.org). There were 18,981 genes
retained in the ﬁnal data set for analysis.
TaqMan
 assay-based real-time RT-PCR
mRNA expression levels of six selected genes that were
statistically signiﬁcantly differentially expressed between
the two tumor groups and/or of biologic interest were
measured in representative tumor specimens by real-time
reverse transcription-polymerase chain reaction (RT-PCR)
using TaqMan
 PRISM 7500 Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA). Gene expression
levels were determined by quantiﬁcation relative to a
control gene, hypoxanthine guanine phosphorbosyl trans-
ferase (HPRT). cDNA was generated using the ABI High
Capacity cDNA Archiving Kit (Applied Biosystems, Foster
City, CA) and RT-PCR reactions were carried out fol-
lowing the manufacturer’s protocol.
Tissue microarrays
Tissue microarrays were constructed as previously descri-
bed [1] using FFPE tumors from 58 BRCA1 carriers, 64
BRCA2 carriers and 242 individuals without BRCA1 or
BRCA2 mutations from the OFBCR. 4 lm thick sections of
these blocks were used for immunohistochemical staining
with the FGFR2 antibody (polyclonal, Abcam). 5 lm thick
sections were used for mRNA in situ hybridization (ISH).
ISH analysis of breast cancer has been reported in detail
elsewhere previously [17]. Brieﬂy, a cDNA probe for ISH
was made to the gene of interest using 33P-UTP-radiola-
beled cRNA. Using routine techniques the TMA sections
were hybridized with the radiolabeled antisense probe,
washed, and treated with Kodak NBT-2 nuclear emulsion.
The sections from the TMAs were stored at 4C for several
weeks prior to development in Kodak D-19 solution; they
were subsequently ﬁxed in Kodaﬁx and counterstained
with 0.1% toludine blue.
Immunoreactivity and mRNA ISH was scored using the
Allred method [18], which combined the intensity of
staining with the percentage of positive tumor cells
observable resulting in a combined score of 0–8. For
FGFR2, a score of 7 or above was considered positive; for
Jagged 1, a previously determined score of 4 or higher [17]
was considered positive.
Statistical analysis
To identify genes that discriminate between BRCA1- and
BRCA2-associatedtumors,supervisedunivariateanalysesof
array-based log2 gene expression were performed for each
clone treating the modiﬁed Student t-test as the primary
analysis[19]usingtheSAMprocedureimplementedinopen
source software, version 2.1.0 (http://www.r-project.org/).
Toassessthesensitivityoftheresultstothisanalysismethod
the random variance test was also applied using BRB Array
Tools (http://linus.nci.nih.gov/BRB-ArrayTools.html). For
each test, all clones were ranked according to their ability to
discriminate BRCA1-associated tumors from BRCA2-asso-
ciated tumors. Supplementary Table 1 reports
discriminating genes with P-values B 0.01 according to the
modiﬁed Student t-test. P-values were not adjusted for
multiple testing.
Log2 transformed relative expression of genes validated
by RT-PCR was compared to array-based log2 gene
expression via scatter plots. Means of the RT-PCR
expressions were compared between the two BRCA tumor
groups using the Student’s t-test and Welch unequal
Breast Cancer Res Treat (2009) 117:183–191 185
123variance t-tests. All tests were two-sided. P-values were
not adjusted for multiple testing.
The proportion of tumors positive by immunohisto-
chemical staining and mRNA ISH for BRCA1-associated
and BRCA2-associated tumors were compared using
Fisher’s exact test for association. All tests were two sided.
Statistical analysis was performed using SAS 9.1 software
(SAS, Institute Inc., Cary, North Carolina). P-values were
not adjusted for multiple testing.
Results
Clinicopathologic characteristics of BRCA1-
and BRCA2-associated tumors
Thirteen tumors were obtained from individuals known to
harbor a BRCA1 or BRCA2 germline mutation. As indi-
cated in Table 1, all of the 13 BRCA-associated tumors
were grade III/III invasive ductal, no special type tumors
(NST). Both ER positive/equivalent and negative tumors
were included among the BRCA1 and BRCA2 carriers. The
mean age at diagnosis of the BRCA1 patients was some-
what younger than the mean age for the BRCA2 subjects
(38 vs. 43 years).
Identiﬁcation of genes that distinguish BRCA1-
and BRCA2-associated breast tumors
ThemodiﬁedStudentt-testwasusedtoidentifyclonesonthe
arrays that were differentially expressed between the
BRCA1-and BRCA2-associatedbreasttumors.There were4
distinguishingcloneswithaP-value\0.001and127clones
with a P-value\0.01. The 150 top-ranked differentially
expressed genes with a P-value of B0.01 are listed in sup-
plementary Table 1 and displayed as a heat map, Fig. 1.
BRCA1-associated tumors were characterized by the
higher relative expression of 52 of these clones. Using the
gene ontology database (NCBI), these genes was predicted
to be involved in diverse cellular functions such as
Fig. 1 Unsupervised two
dimensional cluster analysis of
7 BRCA1-associated and 6
BRCA2-associated breast
tumors. Two dimensional
presentation of transcript ratios
for 13 tumors. The top 150
signiﬁcant genes differentially
expressed between the two
tumor groups from SAM
Moderated t-test are shown.
Each column represents a tumor
and each row a gene. As shown
in the color bar, red indicates up
regulation, green down
regulation and black no change
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123proliferation, angiogenesis, cell motility, cell adhesion,
transcription and DNA repair. Involvement in the MAPK,
Wnt, EGFR and TGFb signaling pathways was identiﬁed.
BRCA1-associated differentially expressed genes included
stathmin/oncoprotein 18 (P = 0.0002), osteopontin
(P = 0.002) and TGFb2 (0.011).
BRCA2-associated tumors preferentially expressed 98 of
the 150 clones. These genes were found to have functions
related to transcription, signal transduction, cell prolifera-
tion, cell adhesion and extracellular matrix remodeling.
Involvement in the MAPK signaling pathway was com-
mon. BRCA2-associated cancers were characterized by the
higher relative expression of FGF1 (P = 0.003) and
FGFR2 (P = 0.004).
Validation of differentially expressed genes
by real time RT-PCR and IHC
To conﬁrm the differences in gene expression, quantitative
real-time RT-PCR was performed for several genes includ-
ing FGF1, FGFR2, stathmin/oncoprotein 18, osteopontin
andTGFb2.DuetolimitedamountsofRNA,only5BRCA1-
and 6 BRCA2-associated tumor RNAs were available for
RT-PCR. Similar to the microarray data, the levels of
expression of osteopontin and TGFb2 were signiﬁcantly
higher in the BRCA1-associated tumors compared to the
BRCA2-associated tumors (P = 0.03 and 0.001, respectively,
Fig. 2).BRCA2-associatedtumorsexpressedhigherlevelsof
FGF1 compared to BRCA1-associated tumors and BRCA1-
associated tumors had higher levels of stathmin/oncoprotein
18 compare to BRCA2-associate tumors, similar to the
microarraydata;butthesedifferenceshowever,didnotreach
statistical signiﬁcance at the 5% level (P = 0.76 and
P = 0.28 respectively, data not shown).
Because the levels of FGFR2 were too low to quantitate
reliably in the tumors using real time RT-PCR we used
immunohistochemistry (IHC) to determine the level of
expression of FGFR2 in an independent set of tumors.
Tissue microarrays were constructed from FFPE tumors
from 64 BRCA2 carriers, 58 BRCA1 carriers and 242
individuals without BRCA1 or BRCA2 mutations. A total of
19 out of 64 (30%) BRCA2-associated tumors stained
positive for FGFR2 compared to 3 of 50 (6%) of BRCA1-
associated tumors (P = 0.004, Fig. 3).
Furthermore, 25 of 151 (17%) breast tumors from non-
mutation carriers were positive for FGFR2, yielding sta-
tistically signiﬁcant differences among the three tumor
groups (P = 0.0007). Further analysis of all tumor groups
suggested that FGFR2 expression was inversely correlated
with the basal phenotype (as deﬁned by the absence of ER,
PR and HER2 expression and the presence of CK 5 or
EGFR expression), with 9 of 65 (13%) basal-like tumors
staining positively for FGFR2 expression compared with
36 of 136 (27%) non-basal-like breast cancers (P = 0.2).
Fig. 2 Scatter plots comparing
the expression ratios of 6 genes
obtained using both cDNA
microarrays and RT-PCR in
BRCA1-associated and BRCA2-
associated tumors. The log2
expression ratios from RT-PCR
(y-axis) and log2 expression
ratios from cDNA microarrays
(x-axis) for 6 genes from
BRCA1-associated (red spots)
and BRCA2-associated (purple
spots) tumors are illustrated in
the scatter plots. The relative
expression ratios for both
modalities for each tumor
correlate positively i.e., RT-
PCR and expression data go in
the same direction (up regulated
or down regulated) for the two
tumor groups
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123More speciﬁcally, FGFR2 negative tumors were more
likely to be ER negative than FGFR2 positive tumors (49.8
vs. 26.7%, P = 0.004, Table 2). Similarly FGFR2 negative
tumors were more likely to be negative for the luminal
cytokeratin CK8/18 and p27 (14.9 vs. 2.2%, P = 0.02 and
36.8 vs. 13.8%, P = 0.01 respectively, Table 2) and more
likely to be positive for the basal cytokeratin CK 5 and
vimentin (32.0 vs. 19.2%, P = 0.08 and 20.3 vs. 5.9%,
P = 0.04 respectively, Table 2). FGFR2 expression was
also positively associated with PR expression (P = 0.01,
Table 2).
BRCA1-associated tumors
Since BRCA1-associated tumors cluster with basal-like
cancers [5, 6, 20], we evaluated whether genes previously
found to be more highly expressed in basal-like tumors
were differentially expressed in the BRCA1 compared to
the BRCA2 groups. Microarray based values of keratin 17,
vimentin and caveolin1 tended to be higher in BRCA1-
associated tumors; however, the differences in expression
of these genes (P = 0.095, 0.067, and 0.233, respectively)
did not meet our global selection cut-off.
Recently we have found that basal-like tumors tend to
exhibit higher expression of Jagged 1 [21], a ligand
involved in Notch pathway signaling. The Notch pathway
has been shown to regulate a number of processes impor-
tant in cancer including angiogenesis [22], epithelial to
mesenchymal transition, and stem-cell like characteristics
[23]. Using RT-PCR we found that the mean expression
level of Jagged 1 tended to be elevated in BRCA1-com-
pared to BRCA2-associated tumors (2.07 versus 0.50,
P = 0.11). Because only 11 tumors were available for RT-
PCR, we examined the expression of Jagged 1 by mRNA
ISH on the TMAs. Of 48 BRCA1-associated tumors, 17
(35%) were positive for Jagged1 by ISH compared to 5 of
53 (9%) BRCA2-associated cancers (P = 0.02, Fig. 3).
Discussion
In recent years, gene expression proﬁling of breast cancers
has improved our understanding of the heterogeneity of the
disease and generated hypotheses concerning the devel-
opment and progression of these cancers. Molecular
signatures for BRCA1-associated tumors have been delin-
eated, but BRCA2-associated tumors have been less well
studied [5, 7]. To elucidate novel genes involved in the
development and progression of BRCA2-associated tumors
and to distinguish distinct pathways of carcinogenesis in
BRCA1 and BRCA2-associated tumors, we compared gene
expression microarray patterns in tumors from BRCA1 and
BRCA2 carriers.
We found that FGFR2 and FGF1 were more highly
expressed in BRCA2-associated cancers as compared to
BRCA1-associated breast cancers, suggesting the presence
of an autocrine growth stimulatory loop. FGF1 and FGFR2
belong to a large family of ligands and receptor tyrosine
kinases [24]. FGF1 is a mitogen that signals through
FGFRs and subsequently activates the MAPK signaling
Fig. 3 Immunohistochemical
and ISH studies on
representative BRCA2-
associated and BRCA1-
associated tumors. Tumor (a)
and (b) are a representative
BRCA2-associated and BRCA1-
associated tumor stained for
FGFR2. The cytoplasmic stain
is positive in tumor (a)a s
evidenced by the intense brown
staining and negative in tumor
(b). Tumors represented in (c)
and (d) are representative
BRCA2-associated and BRCA1-
associated tumors following
ISH for Jagged1 mRNA. Tumor
(c) is negative, with a vessel
acting as a positive internal
control whereas tumor (d)i s
positive
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123cascade. Overexpression of FGF1 in breast cancer cell lines
has been shown to result in increased anchorage indepen-
dent growth and reduced requirement for estrogen in vitro
and to increased tumorigenicity, angiogenesis and meta-
static behaviour in vivo [25, 26]. FGF1 is located at 5q31 a
region of the genome often subject to loss in BRCA1-
associated cancers [27] and basal-like cancers [28].
FGFR2, located at 10q26, encodes at least two receptor
isoforms FGFR2-IIIb and FGFR2-IIIc. FGFR2-IIIc is mainly
expressedintissuesofmesenchymalorigin,whereasFGFR2-
IIIb is expressed in the epithelium of many organs including
the mammary gland [29, 30]. The FGFRs in general and
FGFR2 speciﬁcally have roles in embryogenesis, develop-
mentandcarcinogenesis.FGFR2mRNAisexpressedinmany
carcinomacelllines[31–33]andinthebreastcancercelllines
examined, FGFR2 expression contributes to their invasive
phenotype. Similarly, overexpression of the receptor in nor-
mal human mammary epithelial (HME) cells leads to their
transformation [34]. These properties are attributable to the
activation of the mitogen-activated protein kinase (MAPK)
and phosphatidylinositol 3-kinase (PI3K) signaling cascades
[34].Moreover,thegenelocus(10q26)isampliﬁedin2–10%
of breast cancers and its expression has been reported in 50–
100% of human breast cancers, with high-level expression
conﬁned to 4%–12% of cases [35, 36]. It has also been asso-
ciated with estrogen (ER) and progesterone (PR) receptor
expression and improved overall and disease free survival
[35]. Moreover in two recent independent genome wide
association studies (GWAS) single nucleotide polymor-
phisms (SNPs) within intron 2 of FGFR2 have been causally
associated with increased risk of both familial and sporadic
breast cancer [37, 38]. Furthermore this susceptibility locus
wasassociatedwithyoungerageofonsetandbilateraldisease
[37]. The authors speculate that the SNPs have functional
effects and that the association with breast cancer risk is
mediated through regulation of FGFR2 expression possibly
through interaction with the ER. In our study we have shown
that FGFR2 expression is positively associated with the
BRCA2 genotype, a tumor group that we have previously
shown to be predominantly ER-positive luminal-type tumors
[1]. In addition, we found that FGFR2 expression was posi-
tively associated with PR expression, a weak prognostic and
predictive factor in breast cancer and often regarded as
indicative of a functional ER pathway [39]. Conversely,
FGFR2 expression was negatively correlated with basal-like
breastcancerswhichareknowntobeERnegativeandtocarry
an adverse prognosis [5, 6].
Our expression studies support previous reports indi-
cating that BRCA1-associated breast cancers have a basal-
like proﬁle [3, 5]. In the BRCA1-associated tumor group,
we detected elevated expression of a number of genes,
including keratin 17 [5, 6], vimentin, and caveolin 1 [20],
that have previously been linked to the basal-like cancers.
Our results also suggest that Y-box binding protein-1 is
more highly expressed in BRCA1-associated breast cancers
(P = 0.001). This protein has recently been demonstrated
to transcriptionally induce EGFR which is commonly
overexpressed in basal-like cancers [40]. In addition we
found that stathmin/oncoprotein 18 and osteopontin were
overexpressed in BRCA1-associated tumors relative to
BRCA2-associated tumors. The gene for stathmin, located
at 1p36, is one of the 70 genes that compose the ‘70 gene
classiﬁer’ that predicts poor prognosis in sporadic breast
cancer [41] a classiﬁer that correlates closely with the poor
performing subgroups from the intrinsic gene set of which
basal-like cancers are one [42]. Stathmin is a microtubule
depolymerizing protein involved in cell cycle progression
and cell motility. It is highly expressed in a number of
human malignancies, including breast cancers where it is
negatively correlated with ER expression and positively
correlated with grade, aneuploidy, proliferation and mutant
Table 2 Association between FGFR2 expression and other IHC
markers in all breast tumors (n = 248)
Other marker FGFR2
Positive Negative P-value**
n*% n %
ER
Positive 33 73.3 102 50.3 0.0049
Negative 12 26.7 101 49.8
PR
Positive 30 63.8 88 43.4 0.0113
Negative 17 36.2 115 56.7
Her2
Positive 5 10.6 20 9.9 0.7936
Negative 42 89.4 182 90.1
p27
Positive 25 86.2 110 63.2 0.0152
Negative 4 13.8 64 36.8
p53
Positive 13 27.7 77 38.9 0.1511
Negative 34 72.3 121 61.1
CK818
Positive 44 97.8 172 85.2 0.0207
Negative 1 2.2 30 14.9
CK5
Positive 9 19.2 65 32.0 0.0815
Negative 38 80.9 138 68.0
Vimentin
Positive 2 5.9 36 20.3 0.0445
Negative 32 94.1 141 79.7
* n: number
** Unadjusted P-values are given
Bold values are signiﬁcant at the 5% level
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123p53 [43], all characteristic features of BRCA1-associated
and basal-like cancers [3, 5, 6].
Osteopontin, a secreted phosphoprotein, has been shown to
interact with a diverse range of factors including integrins,
CD44, TGFa, EGFR, Met and VEGF leading to the enhance-
mentofcellularmigration,invasion,survivalandangiogenesis.
[44–46]. Osteopontin is expressed in a wide variety of human
malignancies and its expression has been reported to be cor-
related with poor prognosis in breast cancer [47].
Novel results from our expression study include the
identiﬁcation of members of the Notch and TGFb signaling
pathways, Jagged 1 and TGFb2 respectively, as being more
highly expressed in BRCA1-associated tumors. Both of
these pathways are highly conserved through evolution and
play important roles in development, differentiation and
tumorigenesis [48, 49]. Moreover, both pathways are
known to play a role in mammary stem cell maintenance or
renewal [50, 51]. Dontu et al. have shown that Notch sig-
naling can act on mammary stem cells to promote self-
renewal, on early progenitor cells to promote proliferation,
and on multipotent progenitor cells, facilitating myoepi-
thelial cell lineage speciﬁc commitment and proliferation
[50]. Furthermore, patients whose breast cancers express
Jagged 1 have been found to have a poorer prognosis [17].
Shipitsin and colleagues showed that TGFb signaling is
upregulated in normal breast stem cells and their malignant
counterparts and has prognostic effects [51].
In conclusion, our molecular proﬁling demonstrates that
BRCA1-associated and BRCA2-associated tumors have
distinct molecular proﬁles. Our results conﬁrm the known
link between BRCA1-associated tumors and the basal-like
signature and highlight a link between the Notch and TGFb
pathways and BRCA1-associated tumorigenesis. In contrast
the data suggest that BRCA2-associated tumors express
higher levels of FGFR2 and FGF1, suggesting the exis-
tence of an autocrine loop leading to downstream
pleiotrophic cellular effects.
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